NapiFeryn BioTech has secured a €2.5 million investment led by Icos Capital to enhance its patented technology for extracting rapeseed protein, capitalizing on the growing demand for plant-based alternatives.

Information on the Target

NapiFeryn BioTech Sp. z o.o. ("NapiFeryn"), established in 2014 in Poland, specializes in the innovative extraction of rapeseed proteins from the byproducts generated during the oil pressing process. The company has successfully developed and patented a unique technology capable of producing high-quality plant-based proteins at an affordable price, primarily marketed under the brand name Raptein®. This breakthrough is positioned to significantly contribute to the growing demand for plant-based protein alternatives in food markets, particularly as consumers increasingly seek substitutes for meat and dairy products.

With a focus on utilizing low-value raw materials, NapiFeryn’s technology enhances the value of these resources, allowing for a sustainable approach to protein production. The company operates from BioNanoPark, a renowned science and technology park in Łódź, Poland, which provides a conducive environment for research and development.

Industry Overview in Poland

The food industry in Poland is experiencing a paradigm shift as consumer preferences increasingly lean towards plant-based diets. This trend is driven by concerns over health, sustainability, and animal welfare. As a result, there is a growing demand fo